Why Menopause Causes Hair Loss
Oestrogen and progesterone help maintain the hair growth cycle — extending the anagen (growth) phase and suppressing the effects of androgens on scalp follicles. As oestrogen levels decline during perimenopause and menopause, this protective effect is reduced. The result is an increase in follicle sensitivity to DHT, leading to a pattern of diffuse thinning across the crown and midpart that may accelerate significantly in the years around menopause.
This is distinct from male-pattern baldness — female menopausal hair loss rarely produces the defined receding hairline seen in men, and the frontal hairline is usually preserved. The pattern is typically Ludwig-scale diffuse thinning.
Perimenopause, Menopause or Something Else?
Hair loss in the 40s and 50s is not always menopause acting alone, and telling the causes apart changes what treatment makes sense. Oestrogen decline typically becomes a driving factor for diffuse thinning around this age, but it frequently overlaps with other conditions that produce a similar picture on the scalp — see our full guide to hair loss causes in women for the complete picture. The most common overlaps Dr. Arslan checks for are:
- Perimenopause vs established menopause: During perimenopause, oestrogen fluctuates rather than falling steadily, so shedding can be intermittent and harder to pin down. Once menopause is established and oestrogen settles at a lower baseline, thinning tends to become steadier — which is also when it becomes easier to judge whether it has stabilised enough for surgery to be considered.
- Thyroid dysfunction: Both an underactive and an overactive thyroid can cause diffuse shedding that looks identical to hormonal hair loss on the scalp. A TSH test is one of the first checks requested before attributing loss to menopause alone.
- Iron deficiency anaemia: Low ferritin is a common, reversible contributor to diffuse thinning in women over 40, and frequently compounds menopausal loss rather than replacing it.
- Telogen effluvium: A temporary, stress- or illness-triggered shedding phase that can coincide with menopause but usually resolves within months rather than progressing indefinitely.
Because these causes can overlap, the blood panel described below — not an assumption based on age alone — is what separates a targeted treatment plan from guesswork.
Hormonal and Non-Hormonal Treatments
Before surgical options are considered, non-surgical treatments should be evaluated — many women achieve meaningful stabilisation and some improvement with appropriate medical management.
- Hormone Replacement Therapy (HRT): May slow or reverse hair loss in women whose loss is directly driven by oestrogen decline. The decision to use HRT involves broader health considerations and requires a gynaecologist or endocrinologist's assessment.
- Topical minoxidil (2–5%): The most evidence-supported topical treatment for female pattern hair loss. FDA-approved. Used daily, it can maintain density and produce modest regrowth. Cessation reverses any benefit.
- Oral spironolactone (low-dose): An anti-androgen used off-label in women. Reduces DHT effects. Requires prescription and monitoring.
- PRP therapy: Multiple sessions of scalp injections can support density maintenance. Moderate evidence; useful as an adjunct.
- Nutritional support: Iron deficiency is frequently associated with diffuse hair loss in women. A full panel including ferritin, thyroid function (TSH) and vitamins should be checked before any treatment is initiated.
When Is Hair Transplant Appropriate After Menopause?
Hair transplant surgery can be appropriate for women with menopause-related hair loss under specific conditions. These include: loss that has stabilised on medical management, adequate donor density at the back and sides, specific pattern of loss (hairline recession, traction zones, defined bald areas rather than diffuse thinning), and realistic expectations.
Diffuse thinning across the entire scalp — without a clear stable pattern — is challenging to treat surgically because the donor zone may also be affected. Dr. Arslan assesses each case individually. Women with established, stable traction alopecia or hairline recession following menopause can be excellent candidates for FUE or DHI surgery.
When surgery is the right path, DHI (Choi pen) implantation is generally the preferred technique for menopausal hair loss, as it is for female pattern hair loss generally — grafts are placed between existing hairs without shaving the recipient area, so the procedure stays discreet while it grows in. Graft numbers follow the Ludwig stage and donor capacity rather than a fixed figure: earlier, Ludwig I presentations typically need in the range of 1,000–1,800 grafts, Ludwig II around 1,500–2,500, and more advanced but still stable Ludwig III cases 2,000–3,500 grafts across one to two sessions. The graft calculator gives a starting estimate, but Dr. Arslan confirms the actual number only after examining donor density and loss pattern directly.
The Assessment Process for Women
The assessment protocol for female patients differs from male AGA cases. Dr. Arslan's review includes: photographic analysis of the loss pattern, evaluation of donor zone density and quality, discussion of medical and hormonal history, and a frank conversation about surgical vs non-surgical paths.
Good candidates for surgery
- Hair loss that has stabilised for at least 6–12 months on medical management, rather than actively progressing
- A defined pattern — hairline recession, traction alopecia, or a clearly bordered thinning zone — rather than uniform diffuse loss across the whole scalp
- Adequate donor density at the back and sides, confirmed by direct examination rather than assumed from age or scalp appearance
- Underlying causes such as thyroid dysfunction, iron deficiency or hormonal imbalance already investigated and, where present, treated
Better served by medical management first
- Hair loss that is still actively progressing — grafts placed into an unstable pattern can end up sitting alongside native hair that keeps thinning
- Diffuse thinning that also affects the donor zone, where there may not be enough stable density to harvest from safely
- Untreated thyroid dysfunction, iron deficiency or other blood-panel findings that have not yet been addressed
- Women still deciding on HRT, where hair loss may partially stabilise or improve once the hormonal treatment plan is settled
See our packages and pricing → for more information.
